Skip to main navigation Skip to search Skip to main content

Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

  • Keito Suto
  • , Norio Takei
  • , Keito Yokoyama
  • , Masahiro Chiba
  • , Takashi Ishio
  • , Michiyuki Maeda
  • , Hideki Goto
  • , Tomoyuki Endo
  • , Takanori Teshima
  • , Yibin Yang
  • , Masao Nakagawa
  • Hokkaido University
  • Kyoto University

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

Correction to: Leukemiahttps://doi.org/10.1038/s41375-024-02441-1, published online 21 October 2024 The BV concentration units were incorrectly labeled as pM due to an error in molar conversion. The correct unit used in all experiments was nM. This labeling error appears in the following sections: Figures: 1D, 2A, 2B, 2C, 2F Supplementary Figures: 1A, 1D, 3B, 4G, 5B, 5C Supplementary Materials and Methods: Genome-wide CRISPR library screen The original article has been corrected.

Original languageEnglish
Pages (from-to)3061
Number of pages1
JournalLeukemia
Volume39
Issue number12
DOIs
StatePublished - Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma'. Together they form a unique fingerprint.

Cite this